InVentiv Health, Inc

InVentiv Health, Inc. is a biopharmaceutical solutions organization that provides comprehensive services across clinical development, regulatory affairs, and commercialization to accelerate the delivery of therapies to market. InVentiv Health operates as a biopharmaceutical solutions provider. Founded in 1999 in Burlington, US, it was involved in various deals and underwent a significant Merger with INC Research Holdings Inc.

, valued at USD 4. 6 billion, completed in August 2017. The founder, Harley Jagpal, has a background in healthcare and business, leading the company to a robust operational framework under CEO Michael Bell. InVentiv Health provides a full range of services in the biopharmaceutical sector, including clinical development, regulatory affairs, and commercialization strategies.

Their expertise spans therapeutic areas such as oncology and hematology, leveraging technology and insights to streamline drug development from preclinical stages through to market introduction. They work primarily B2B with biopharmaceutical clients globally, offering tailored solutions that reflect their specialized capabilities. In 2015, InVentiv Health reported a revenue of USD 2,321. 27 mn and an EBITDA of USD 187.

27 mn, generated through service agreements with biopharmaceutical companies, structured as project-based contracts focusing on clinical trials and regulatory support. The merger in May 2017 with INC Research Holdings has positioned InVentiv Health for future growth, aiming to expand its service offerings and geographic reach. The combined entity is set to leverage its larger scale to enhance its product portfolio and enter new markets. The newly formed Syneos Health, with an enterprise value of USD 7.

4 bn, aims to utilize the merger efficiencies and synergies to develop new products, enhance service delivery, and improve operational efficiencies in the biopharmaceutical sector.